What medication is recommended for intermittent hot flashes?

Recommended Treatment for Intermittent Hot Flashes

For intermittent hot flashes, start with an SSRI (paroxetine 7.5-25 mg or venlafaxine 75-150 mg) or gabapentin 900-2400 mg, as these are the most effective nonhormonal prescription options with the best evidence for reducing vasomotor symptoms by approximately 60-70%. 1

Treatment Algorithm

First-Line Nonhormonal Options

The 2015 Endocrine Society guidelines establish a clear hierarchy for nonhormonal prescription therapies 1:

• SSRIs/SNRIs: Paroxetine, venlafaxine, desvenlafaxine, citalopram, or escitalopram

  • Reduce hot flash composite scores (frequency × severity) by 60-70%
  • Venlafaxine is preferred by most patients when compared head-to-head with gabapentin (two-thirds preferred it despite equal efficacy) 1
  • Generally well tolerated with manageable side effects

• Gabapentin: 900-2400 mg daily (typically 300 mg three times daily)

  • Reduces hot flash scores by approximately 66%
  • Best taken at bedtime because sedating effects work synergistically with its vasomotor effects and dissipate by morning 1
  • Daytime use may cause intolerable lethargy

• Pregabalin: 150-300 mg daily (75-150 mg twice daily)

  • Reduces hot flash scores by 65-71% 1
  • May impair memory and concentration more than gabapentin

Choosing Between First-Line Options

Select based on timing and tolerability needs:

• If hot flashes are predominantly nocturnal → gabapentin at bedtime (leverages sedative effects)
• If hot flashes occur throughout the day → SSRI/SNRI (venlafaxine or paroxetine preferred based on patient preference data)
• If patient has comorbid depression or anxiety → SSRI/SNRI provides dual benefit

Second-Line Option

Clonidine (transdermal patches preferred over tablets for stable blood levels) 1

• Only if not responding to or tolerating SSRIs/SNRIs, gabapentin, or pregabalin
• Less effective than first-line agents with more side effects
• Contraindicated with low blood pressure; causes lightheadedness, hypotension, headache, constipation 1, 2

Important Caveats

Contraindications to Monitor

SSRIs/SNRIs 1:

• Prior neuroleptic or serotonin syndrome
• Concurrent MAO inhibitor use
• Use cautiously with: bipolar disease, uncontrolled seizures, hepatic/renal insufficiency, poorly controlled hypertension
• Monitor for suicidal thoughts in first few months
• Possible increased bone fracture risk

Gabapentin/Pregabalin 1:

• May increase suicidal thoughts and behaviors
• Cause drowsiness, dizziness, impaired balance and coordination
• Pregabalin specifically may impair memory and concentration

Efficacy Context

While standard-dose menopausal hormone therapy (MHT) is more effective than nonhormonal agents (80-90% reduction vs 60-70%), the nonhormonal options above represent the best alternatives when hormones are contraindicated or refused 1, 3.

Avoid clonidine, methyldopa, and belladonna as first-line due to modest efficacy and adverse effects 3.